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Abstract Uncontrolled proliferation is one of the hall-
marks of breast cancer. We have previously identified the
human Ecd protein (human ortholog of Drosophila Ecdy-
soneless, hereafter called Ecd) as a novel promoter of
mammalian cell cycle progression, a function related to its
ability to remove the repressive effects of Rb-family tumor
suppressors on E2F transcription factors. Given the fre-
quent dysregulation of cell cycle regulatory components in
human cancer, we used immunohistochemistry of paraffin-
embedded tissues to examine Ecd expression in normal
breast tissue versus tissues representing increasing breast
cancer progression. Initial studies of a smaller cohort
without outcomes information showed that Ecd expression
was barely detectable in normal breast tissue and in
hyperplasia of breast, but high levels of Ecd were detected
in benign breast hyperplasia, ductal carcinoma in situ
(DCIS) and infiltrating ductal carcinoma (IDCs) of the
breast. In this cohort of 104 IDC patients, Ecd expression
levels showed a positive correlation with higher grade
(P = 0.04). Further analyses of Ecd expression using a
larger, independent cohort (954) confirmed these results,
with a strong positive correlation of elevated Ecd expres-
sion with higher histological grade (P = 0.013), mitotic
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index (P = 0.032), and Nottingham Prognostic Index score
(P = 0.014). Ecd expression was positively associated
with HER2/neu (P = 0.002) overexpression, a known
marker of poor prognosis in breast cancer. Significantly,
increased Ecd expression showed a strong positive asso-
ciation with shorter breast cancer specific survival (BCSS)
(P = 0.008) and disease-free survival (DFS) (P = 0.003)
in HER2/neu overexpressing patients. Taken together, our
results reveal Ecd as a novel marker for breast cancer
progression and show that levels of Ecd expression predict
poorer survival in Her2/neu overexpressing breast cancer
patients.
Keywords Ecdysoneless  Cell cycle  Breast cancer 
HER2/neu  DCIS  IDC
Introduction
Breast cancer still remains the most frequent cancer of
women with nearly a million new cases worldwide each
year with about 400,000 deaths annually [1]. Delineating
the molecular pathways that contribute to aggressive
behavior of human breast cancers to identify newer prog-
nostic markers and therapeutic targets is therefore a critical
research priority. The most important prognostic factor in
breast cancer remains the lymph node status, which
strongly correlates with disease-free and overall survival.
Additional markers that have now become linked to
molecular classification of breast cancer subtypes include
the expression of hormone receptors (ER and PR) that
predicts response to endocrine therapy and overexpression
of HER2/neu status that predicts response to anti-HER2/
neu therapy with Trastuzumab. Concurrently, ER ?/PR ?
tumors have a more favorable prognosis while HER2/neu
overexpression signifies a markedly worse prognosis.
Absence of ER, PR and HER2/neu in the so called triple-
negative breast cancers is also associated with a poor
prognosis. Identification of newer molecular pathways
important in oncogenesis is therefore expected to provide
additional useful prognostic and predictive markers to help
in the selection of appropriate targeted therapies and could
provide new therapeutic targets.
Uncontrolled proliferation is a hallmark of cancer and it
has now become clear that major drivers of breast cancer
oncogenesis enhance the expression and/or activity of cell
cycle progression-associated genes [2]. Extensive research
over the past two decades has led to our current model of how
quiescent cells enter cell cycle [3, 4]. E2F family tran-
scription factors play a critical role to turn on the expression
of a large set of genes required for cell cycle progression [5].
These transcription factors are held in a repressive complex
by their association with hypophosphorylated form of the
Retinoblastoma (Rb) protein family members (Rb/p105,
p107 and Rb2/p130) [6]. Phosphorylation of Rb proteins by
cell cycle-associated cyclin-dependent kinases (CDKs) [7–
9] helps dissociate the Rb proteins from E2Fs, resulting in
the transcription of E2F target genes [6, 10]. Consistent with
this basic paradigm, genetic alterations of cell-cycle
machinery components are frequent in cancer [11–15]. Thus,
analyses of novel cell cycle regulatory components provide
an opportunity to discover new prognostic markers in breast
cancer.
Recently we identified a protein called Ecdysoneless as a
novel cell cycle regulator. Ecd interacts with Rb and
facilitates its separation from E2Fs [15]. Genetic deletion of
Ecd in mice is embryonic lethal, while conditional deletion
of Ecd in MEFs leads to retardation of the separation of Rb
from E2F, delay/reduction in E2F-dependent gene expres-
sion and block in cell cycle progression. Therefore, we
sought to investigate if the status of expression of Ecd might
serve as a novel prognostic/predictive marker for breast
cancer. To this end, we have analyzed a large set of breast
cancer tissue specimens with known clinical parameters and
our findings establish the overexpression of Ecd as a new
prognostic marker for breast cancer.
Materials and method
The breast cancer tissue specimens used in the present
study came from two independent patient cohorts as
described below.
Cohort1 comprises of 269 breast cancer tissue speci-
mens that were obtained from the Department of Pathol-
ogy, Evanston Northwestern Healthcare (ENH; now
renamed as Northshore University Health System Research
Institute) or the Department of Pathology and Microbiol-
ogy, University of Nebraska Medical Center (UNMC) or
purchased as tissue arrays from US Biomax (US Biomax,
Inc.Rockville, MD, USA). In this collection, 194 speci-
mens were derived from patients with IDC (95 from ENH,
32 from UNMC and 67 from US Biomax tissue arrays). For
comparison, the collection included 29 normal reduction
mammoplasty specimens (19 from ENH and 10 from
UNMC), 10 benign hyperplasia specimens (ENH) and 36
DCIS specimens (ENH). The tissue specimens at ENH and
UNMC were obtained after Institutional Review Boards
reviewed and approved the protocols.
Cohort 2 include Formalin fixed paraffin embedded tis-
sue microarrays prepared from a series of cases of primary
operable (stage I and II) breast carcinoma cases from
patients age \70 presenting consecutively to the Notting-
ham Breast Unit with tumors of less than 5 cm diameter
between 1988 and 1998 as previously reported [16]. This
consecutive patient series is well characterized and contains
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clinical and pathological data including patients’ age, his-
tological tumor types, primary tumor size, lymph node
status, mitotic count and histological grades [17], Notting-
ham prognostic index (NPI) [18], vascular invasion (VI),
therapy and follow-up data. Outcomes data include the
survival status, survival time, cause of death, and disease
free interval (DFI). The Breast Cancer Specific Survival
(BCSS) is defined as time (in months) from the date of
primary surgery to the date of breast cancer-related death.
DFI is defined as the duration (in months) from the date of
primary surgery to the appearance of loco-regional recur-
rence or distant metastasis. In addition, data on a large panel
of biomarkers with strong relevance to breast cancer were
available including ER, PR, HER2/neu, cytokeratins (CKs;
basal CKs: CK5/6), p53 protein, and proliferation marker
Ki67. The median age of patients was 55 years (range
18–70 years) with a median overall survival of 126 months
(range 4–243 months) and median time of event-free sur-
vival of 114 months (range 2–243 months). Distant recur-
rence occurred in 501 cases (28%). 454 (25%) patients died
from breast cancer, while 1,024 (58%) patients were alive at
the end of follow-up.
Immunohistochemical analysis of Ecd expression
Formalin-fixed paraffin tissue sections (4 lm) or breast
cancer tissue microarrays [19] were deparaffinized in
xylene, rehydrated in descending alcohols and treated in a
digital pressure cooker containing citrate buffer (pH 6.0;
DakoCytomation, S1699). Endogenous peroxidase activity
was blocked by incubation in 3% hydrogen peroxide for
10 min. The sections were rinsed in Tris-buffered saline
with Tween and incubated for 15 min in Protein-Block
buffer (DakoCytomation X0909) and sections were stained
with primary monoclonal anti-bodies against Ecd (generated
by us) overnight at 4C. After rinsing in TBST, the sections
were incubated for 15 min with anti-mouse antibody con-
jugated to a dextran-labeled polymer and HRP (DakoCyto-
mation K4007) secondary, later on DAB solution for 7 min
was added (DakoCytomation DAB ? K4007, Solution 3a, b).
The sections were then counter-stained in Mayer’s hema-
toxylin (Sigma MHS-80) and mounted under cover glasses
using a xylene-based mounting medium.
Scoring of staining
For cohort 1, the Ecd staining intensity was evaluated
under a light microscope by six independent observers
including three of our pathology collaborators, and
expressed on a scale of 0 to 3: 0, no staining; 1, weak; 2,
moderate; 3, strong.
For cohort 2, the stained TMAs sections were manually
scored from high-resolution digital images (NanoZoomer,
Hamamatsu Photonics, Welwyn Garden City, UK) obtained
at 209 magnification, using a web-based interface (Distiller,
Slidepath Ltd., Dublin, Ireland) and percentage staining was
determined. The cut-point for dichotomization was deter-
mined using X-tile bio-informatics software. The optimal cut-
points were determined by locating the brightest pixels on the
X-tile plot diagram of the training set. Statistical significance
was tested by validating the obtained cut-point to the vali-
dation set [20]. All cases were scored without prior knowl-
edge of the clinicopathological stages or outcomes data.
Generation of Ecd monoclonal antibody
Full length human Ecd cDNA was cloned into pProEx HT
bacterial expression vector (that contain N-terminal 69
Histidine tag). The recombinant protein (hEcd) was purified
from a large scale culture of BL21 E coli using Ni–Nta col-
umns. The purified hEcd (with N terminal 69 histidine tag)
was used as an antigen to produce monoclonal antibodies at
the Monoclonal Antibody Core Facility, Lurie Cancer Cen-
ter, Northwestern University, Chicago. The clones were
screened by (i) western blotting with anti-flag or anti-Ecd
antibodies, using flag-tagged Ecd overexpressing 293T cell
lysates and also by (ii) immunoprecipitation of endogenous
or exogenous Ecd from 293T cell lysates (data not shown). A
few well reacting antibodies were selected among which the
clone 4A8 was used for subsequent experiments. Clone 4A8
recognized a single band of estimated size in western blotting
and immunoprecipitation as previously described [15].
Validation of Ecd antibody specificity
for immunohistochemistry
For validation of Ecd antibody specificity for immunohis-
tochemical analyses, 76 N.TERT cells (hTERT-immortal-
ized normal human mammary epithelial cells) with or
without hEcd overexpression or Ecd knockout (MEF
Ecd-/-) and wild type mouse embryonic fibroblasts (MEF
Ecd?/?) [15] were cultured on coverslips, fixed with 4%
paraformaldehyde and stained with anti-Ecd antibody, as
above. Western blotting was performed on whole cell
lysates of 76 N.TERT cells or MEFs using a 1:2,000
dilution of anti-Ecd antibody, as previously described [15].
Statistical analysis
Statistical analysis was performed using the SPSS 16.0 sta-
tistical software (SPSS Inc., Chicago, IL, USA). The
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Kruskal–Wallis and v2 tests were used to determine rela-
tionships between various variables. Cut-off values for the
different biomarkers included in this study were chosen
before statistical analysis. Standard cut-offs were used for
established prognostic factors and were the same as previ-
ously published for this patient series [21, 22]. Determina-
tion of the optimal Ecd cut-offs were performed using the
X-tile bioinformatics software, version 3.6.1, 2003–2005,
Yale University, USA. Analysis of categorical variables was
performed with the appropriate statistical test. Survival
curves were analyzed using the Kaplan–Meier method with
significance determined by the Log Rank test. Multivariate
analysis was performed using the Cox hazard analysis. A p
value of 0.05 or lower was considered significant.
Results
Validation of the specificity of anti-Ecd monoclonal
antibody for immunohistochemical staining
We have previously generated an anti-Ecd monoclonal
antibody and established its specific recognition of both the
human and mouse Ecd proteins in western blot [15, 23, 24].
Furthermore, we have shown that Ecd shuttles between the
nucleus and the cytoplasm with a fast nuclear export
resulting in a predominantly cytoplasmic localization in
cells [23].
In order to assess the specificity of anti-Ecd monoclonal
antibody in IHC staining, retroviral infection was used to
overexpress Ecd in 76N. TERT human mammary epithelial
cell line and compared with vector-infected cell line for IHC
staining anti-Ecd mAb or nonspecific IgG as a staining
negative control. As expected, essentially no staining was
observed with the IgG control. Importantly, compared to a
faint staining with anti-Ecd staining of vector-infected cells,
a strong cytoplasmic signal was observed in Ecd-over-
expressing (Supplementary Fig. 1a). Western blotting cor-
related with the IHC staining (Supplementary Fig. 1b). To
further confirm the specificity of IHC staining of Ecd, we
derived Ecd-null MEFs by adenovirus-Cre infection of Ecdfl/
fl MEFs [15]. While specific Ecd staining was seen in MEFs
without induced Ecd deletion, no staining was seen in MEFs
with induced Ecd deletion (Supplementary Fig. 1c and 1d).
Finally, we validated anti-Ecd staining by performing initial
IHC staining of a small number of breast tumor specimens
that contained adjacent normal tissue within the same sec-
tion. While strong staining was observed in the tumor area,
little staining was observed in the adjacent normal tissue
(Fig. 1a–c). Altogether, these initial studies validated the use
of our mAb for IHC staining, established its specificity, and
suggested that Ecd protein levels were higher in breast tumor
tissues compared to normal breast tissues.
Markedly increased Ecd expression in DCIS and IDC
in comparison with normal breast tissues
and hyperplasia
As Ecd functions to promote cell cycle progression, we
assessed the relative Ecd expression by comparing the
intensity of IHC staining with anti-Ecd mAb in 36 DCIS
and 95 IDC tissue specimens in comparison with 19 normal
breast tissues. In addition, we also performed similar
analyses in 10 breast hyperplasia specimens. A clear
cytoplasmic staining was observed in DCIS and IDC tumor
tissues, whereas little or no staining was observed in nor-
mal breast tissues; interestingly, a similar low or no
staining was observed in breast hyperplasia tissue speci-
mens (Fig. 2a; Table 1). Expression of Ecd staining
intensity according to the numeric scale indicated that none
of the normal breast tissue specimen showed a high level of
Ecd staining (score 2 or 3); while 20% of hyperplasia
specimens showed a medium (score 2) level of Ecd stain-
ing, none scored at level 3 (Fig. 2b). In contrast, 17% of
DCIS and 31% of IDC specimens showed a high level Ecd
staining (score 3) (Table 1). These results suggested that
the levels of Ecd expression may positively correlate with
increasing grade of breast tumors.
Ecd expression correlates positively with increasing
tumor grade in IDC specimens
Next, we examined an additional 104 IDC specimens within
cohort 1 where tumor grade information was available. We
Magnification:10X
a b cFig. 1 IHC staining of IDC and
adjacent normal duct. Three
independent IDC (a–c) tumor
specimens which contain
adjacent normal ducts were used
for IHC staining using anti-Ecd
antibodies. Arrows indicate Ecd
staining in tumor tissues and
arrow heads indicate Ecd
staining in the adjacent normal
ducts at a magnification of 910
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observed a statistically significant positive correlation
(P = 0.04) between the levels of Ecd expression and grade
of IDC with high-grade cancers showing higher levels of
Ecd protein (Supplementary Table 1, Fig. 2b).
Association of Ecd overexpression
with clinicopathological parameters of poor prognosis
Cytoplasmic Ecd expression was dichotomised into neg-
ative-moderate (B 70% cytoplasmic staining) and high
([70% cytoplasmic staining) categories. Using these cut-
points, a minority of patients (214 cases; 22.4%) showed
negative-moderate levels of Ecd expression while a
majority (740 cases; 77.6%) showed high levels of Ecd
expression in cohort 2. High Ecd expression was posi-
tively associated with higher tumor grade (P = 0.013)
(Table 2), further validating observations made with
cohort 1. A positive correlation was also observed
between high Ecd expression and known markers of poor
prognosis, including increased mitotic index (P = 0.032)
and poor NPI group (P = 0.014). No association between
the levels of Ecd expression and other parameters
observed (Table 2).
Ecd expression shows a positive correlation
with positive HER2/neu but not ER/PR status
Next we examined if the levels of Ecd expression correlate
with molecular markers of breast cancer subtypes, ER/PR
and HER2/neu. Notably, we observed a positive associa-
tion between high Ecd expression and HER2/neu-positive
status (P = 0.002) (Table 3). In contrast, we did not
observe an association of Ecd expression with ER ?,
PR ?, ER ?/PR ? or triple negative status (Table 3). The
levels of Ecd expression also showed no association with
p53 or Ki67 expression. Considering that a subtype of
breast cancers is categorized by HER2/neu positive and
expression of HER2/neu predicts poor outcome in patients,
association of HER2/neu with Ecd is highly significant and
could serve as a marker for poor outcome of patients.
The levels of Ecd expression correlate with disease
outcome in breast cancer patients
In view of a positive association of the levels of Ecd
expression with several prognostic factors, we wished to
assess if Ecd expression could predict the outcome of
disease in breast cancer patients in cohort 2 where out-
comes data was available. For this purpose, the estimated
predictive power of Ecd expression was assessed using the
Kaplan–Meier survival analysis. Patients with high Ecd
expression exhibited a statistically significant reduction
term for BCSS (120 months, P = 0.008) as compared to
patients with no to moderate Ecd expression (Fig. 3a).
These results suggest that Ecd expression can serve as a

















Fig. 2 a Analyses of Ecd
expression in normal, DCIS and
IDC breast tissues.
Representative specimens (from
Table 1) for Ecd staining are
shown with magnification of
940; b Correlation of Ecd
expression in samples from
cohort 1 with IDC tumor grade
is shown. The distribution of
IDC samples was: grade
1 = 18, grade 2 = 34, and
grade 3 = 52, analyzed by
Kruskal–Wallis test
Table 1 Ecd expression in DCIS and IDC in comparison with nor-
mal and hyperplasia
Tissue type Normal Hyperplasia DCIS IDC
Score N (%) N (%) N (%) N (%)
0 17 (89) 4 (40) 8 (22) 19 (20)
1 2 (10) 4 (40) 8 (22) 15 (16)
2 0 (0) 2 (20) 14 (39) 32 (34)
3 0 (0) 0 (0) 6 (17) 29 (31)
Breast Cancer Res Treat (2012) 134:171–180 175
123
Co-expression of Ecd predicts poorer outcome
in HER2/neu ? breast cancer patients
Next, we assessed whether levels of Ecd expression might
predict different outcomes in HER2/neu ? patients. For
this purpose, we correlated Ecd expression levels in
HER2/neu ? patients with disease free survival as well as
overall survival. This analysis revealed that the overall
survival in HER2/neu ? patients that expressed high
levels of Ecd was significantly worse (P = 0.008) as
Table 2 Relationship between
Ecd expression and various
clinicopathological parameters
Parameter Ecd expression Significance
Low Ecd High Ecd Total P value
No. (%) No. (%) No. (%)
Patients age
B50 years 88 (41.1) 265 (35.8) 353 (37) 0.156
[50 years 126 (58.9) 475 (64.2) 601 (63)
Total 214 740 954
Tumor size
B1.5 cm 72 (33.6) 212 (28.8) 284 (30) 0.181
[1.5 cm 142 (66.4) 522 (71.1) 664 (70)
Total 214 734 948
Lymph node stage
1 132 (61.7) 423 (57.6) 555 (58.5) 0.395
2 67 (31.3) 240 (32.7) 307 (32.4)
3 15 (7) 71 (9.7) 86 (9.1)
Total 214 734 984
Grade
1 41 (19.2) 102 (13.9) 143 (15.1) 0.013
2 74 (34.6) 211 (28.7) 285 (30.1)
3 99 (46.3) 421 (57.4) 520 (54.9)
Total 214 734 984
Tubules
1 14 (6.7) 33 (4.6) 47 (5.1) 0.273
2 70 (33.7) 218 (30.5) 288 (31.2)
3 124 (59.6) 463 (64.8) 587 (63.7)
Total 208 714 922
Pleomorphism
1 5 (2.4) 6 (0.8) 11 (1.2) 0.151
2 73 (35.3) 237 (33.3) 310 (33.8)
3 129 (62.3) 468(65.8) 597(65)
Total 207 711 918
Mitosis
1 76 (36.5) 216 (30.3) 292 (31.7) 0.032
2 46 (22.1) 29 (18.1) 175 (19)
3 86 (41.3) 369 (51.7) 455 (49.3)
Total 208 714 922
Nottingham prognostic index
Good (3.4) 69 (32.2) 185 (25.3) 254 (26.8) 0.014
Moderate (3.41–5.4) 117 (54.7) 393 (53.7) 510 (53.9)
Poor(4.41–5) 28 (13.1) 154 (21) 182 (19.2)
Total 214 732 946
Vascular invasion
Definite 61 (29) 253 (34.4) 314 (33.2) 0.145
Negative 149 (71) 482 (65.6) 631 (66.7)
Total 210 735 945
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compared to HER2/neu ? patients with no to moderate
Ecd expression. Furthermore, HER2/neu ? patients with
high levels of Ecd showed significantly reduced DFS
(250 months, P = 0.003) as compared to HER2/neu ? -
patients with no to moderate Ecd expression (Fig. 3b, c).
However, Cox-multivariate regression analysis revealed
that Ecd expression as a predictor of BCSS was not
independent of tumor size, stage or grade (P = 0.126)
(Table 4). Taken together, Ecd overexpression predicts
poor prognosis and outcome in HER2/neu positive
patients.
Discussion
Breast cancer has emerged as group of diseases that are
clinically and molecularly diverse and carry significantly
different outcomes. Thus, newer prognostic markers that
can help predict the course of disease, either by themselves
or in association with established markers, can help devise
better treatment strategies. Here, we have investigated the
levels of expression of a novel cell cycle regulator Ecd in
breast cancer patient specimens as a potential prognostic
biomarker. Our studies show that expression of high levels
Table 3 Relationship between
Ecd expression and other
biomarkers
Parameter Ecd expression Significance
Low Ecd High Ecd Total P value
No. (%) No. (%) No. (%)
ERa status
Negative 47 (22.3) 206 (28.6) 253 (27.1) 0.070
Positive 164 (77.7) 515 (71.4) 679 (72.9)
Total 211 721 932
PgR status
Negative 78 (38) 303 (42.9) 381 (41.8) 0.213
Positive 127 (62) 403 (57.1) 530 (58.2)
Total 205 706 911
HER-2 status
Negative 191 (92.3) 612 (84) 803 (85.8) 0.002
Positive 16 (7.7) 117 (16) 133 (14.2)
Total 207 729 936
ER.PR. status
ER-PR- 44 (21.8) 197 (28.5) 241 (27) 0.29
ER-PR? 1 (0.5) 2 (0.3) 3 (0.3)
ER ? PR- 31 (15.3) 95 (13.7) 126 (14.1)
ER ? PR? 126 (62.4) 397 (57.5) 523 (58.6)
Total 202 691 893
Triple negative status
Non-TN 172 (82.3) 587 (81.4) 759 (81.6) 0.772
TN 37 (17.7) 134 (18.6) 171 (18.4)
Total 209 721 930
Basal type
Negative 153 (73.6) 559 (80.3) 712 (78.8) 0.037
Positive 55 (26.4) 137 (19.7) 192 (21.2)
Total 208 696 904
p53
Negative 154 (75.1) 494 (71.1) 648 (72) 0.257
Positive 51 (24.9) 201 (28.8) 252 (28)
Total 205 695 900
Ki67
Moderate 145 (79.2) 455 (75.8) 600 (76.6) 0.341
High 38 (20.8) 145 (24.2) 183 (23.4)
Total 183 600 783
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of Ecd protein correlates with several known markers of
poor prognosis in breast cancer, and predicts poorer breast
cancer-specific survival, especially in the HER2/neu ? -
breast cancer.
Ecd is an evolutionarily-conserved protein that we have
demonstrated to be an essential component of mammalian
cell cycle progression [15, 24]. Ecd plays an essential role in
facilitating the removal of Rb-family of tumor suppressor
proteins from E2F transcription factors such that lack of
Ecd leads to prolonged Rb-E2F association and inhibition
of cell cycle progression. In cell culture studies, we have
observed that ectopic overexpression of Ecd in human
mammary epithelial cells promotes proliferation (unpub-
lished). To assess the expression of Ecd in breast cancer, we
first established the ability of a monoclonal antibody gen-
erated in our laboratory to specifically detect in a quanti-
tative manner the expression of human Ecd. By utilizing
WT versus Ecd-null MEFs and human mammary epithelial
cells with overexpression of Ecd versus vector controls, we
established the ability of our mAb anti-Ecd to specifically
detect Ecd and to provide an assessment of different levels
of Ecd expression in a cell-based IHC. Importantly, this
staining format was successfully adapted to paraffin-
embedded human breast tissue specimens. Notably, these
initial studies with breast tissue specimens from a smaller
cohort that included normal reduction mammoplasty,
benign hyperplasia, DCIS and IDC samples provided the
first indication that Ecd expression increased in tissues with
breast cancer progression: while essentially little Ecd sig-
nals were observed in normal breast tissue and hyperplasia,
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Table 4 Multivariate COX regression model for predictors of BCSS
in patient cohort
Variable P value HR 95% CI
Lower Upper
Ecd 0.126 2.34 0.539 1.079
Tumor size 0.00 13.86 0.313 0.697
Tumor stage 0.00 34.13 1.448 2.104
Tumor grade 0.00 40.02 1.799 3.046
Fig. 3 a Kaplan–Meier plot of Ecd expression in the whole series of
breast cancer patients with respect to BCSS for 120 months
(P = 0.008); b Kaplan–Meier plot of Ecd expression in Ecd alone,
HER2 alone or HER2 ? Ecd overexpressing breast cancer patients
with respect to BCSS for 250 months (P = 0.04); c Kaplan–Meier
plot of Ecd expression in Ecd alone, HER2 alone or HER2 ? Ecd
overexpressing breast cancer patients with respect to DFI for
250 months (P = 0.008)
b
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Analyses of patient cohort 1 showed a clear overex-
pression of Ecd in 56% of DCIS and 65% of IDC samples
as compared to no or little expression of Ecd in normal and
hyperplasia specimens. Two major conclusions arose from
these analyses: (i) that Ecd is overexpressed starting at an
early stage of breast cancer i.e. DCIS; (ii) that Ecd is
overexpressed in IDC but not in normal and hyperplasia
samples, suggesting that levels of Ecd expression could
provide a potential marker of breast cancer progression.
Indeed, further analyses using cohort 2 of IDC tissue
specimens showed a positive association of Ecd expression
with tumor grades. Furthermore, Ecd expression showed a
significant positive correlation with the mitotic index, a
result consistent with the role of Ecd in cell cycle pro-
gression [15].
Further analyses using a large cohort of breast cancer
patient specimens with associated clinical outcomes data
helped assess if the levels of Ecd overexpression correlate
with patient outcome. Kaplan–Meier survival analysis
showed that patients with high Ecd expression have a
significantly reduced BCSS (120 months, P = 0.008).
These results suggest that Ecd expression could serve as a
marker of disease-specific survival outcome in breast
cancer patients.
The expression of ER, PR and HER2/neu provides
useful markers to help in the choice of post-operative
adjuvant therapy with the strongest likelihood of better
outcomes. The triple negative patients show a higher
likelihood of disease recurrence and metastatic disease
with poor overall survival, reflecting both the biology of
these tumors and the current lack of suitable targeted
therapies for this subset. It is notable that the maximum
difference in the outcomes of TNBC versus other forms of
breast cancer are seen at 3 years after diagnosis and the
differences gradually diminish year by year for up to
10 years [25, 26]. Thus, we speculate that Ecd expression
could provide a useful additional prognostic marker for use
in conjunction with the established clinical-pathological
prognostic markers.
Notably, our studies revealed that co-expression of high
levels of Ecd in the HER2/neu ? subset of patients pre-
dicted a significantly poorer outcome both in terms of
overall and breast cancer specific survival. While the
availability of HER2/neu-targeted therapies has signifi-
cantly improved the outcomes of patients with HER2/
neu ? breast cancer, this subset of breast cancers continues
to be associated with poorer outcomes compared to ER ?/
PR ? tumors, and treatment-associated toxicities and high
incidence of de novo and acquired resistance to Trast-
uzumab continue to be significant impediments in treat-
ment. Thus, additional markers that might improve the
prediction of outcomes in this subset of patients could
help physicians and patients in deciding on options for
conventional versus aggressive treatment strategies. While
there are no known catalytic domains in Ecd to make it
conventionally druggable, the increasing ability of
researchers to design inhibitors that work by non-conven-
tional mechanisms suggest that further studies in this
direction are warranted.
It is notable that Ecd protein overexpression in breast
cancer is not accompanied by increase in its mRNA levels
(unpublished). This explains the lack of overexpression
observed in microarray data and points to the need to
further establish the mechanisms by which Ecd is overex-
pressed in breast cancer. Further studies will be needed to
assess if translational and/or post-translational mechanisms
contribute to Ecd overexpression.
In conclusion, studies presented here identify the over-
expression of cell cycle regulatory protein Ecd as a
potential prognostic marker in breast cancer. Ecd overex-
pression positively correlates with increasing tumor pro-
gression, predicts poorer overall and breast cancer-specific
survival and defines a subset of HER2/neu ? patients with
a particularly worse outcome. As Ecd is expressed in a
variety of normal tissues, further studies to assess Ecd
overexpression in other tumors should help assess its broad
role as a prognostic marker as well as help link its over-
expression to oncogenesis of other organs.
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